Clinical trial
Rosiglitazone (Avandia®) Treatment in HIV: Its Effect on Blood Vessels
NCT00143624 · University of British Columbia, Other · Completed
Key facts
| NCT number | NCT00143624 |
|---|---|
| Title | Rosiglitazone (Avandia®) Treatment in HIV: Its Effect on Blood Vessels |
| Official title | Effect of Rosiglitazone Maleate (Avandia®) on Carotid Intima Media Thickness, Brachial Artery Reactivity, Glucose Metabolism, Blood Lipid Concentrations, Body Fat Distribution, and Biochemical Markers of Cardiovascular Risk in Patients With the HIV Metabolic Syndrome |
| Lead sponsor | University of British Columbia, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Atherosclerosis, HIV Infections |
| Intervention type | Drug |
| Interventions | Rosiglitazone maleate, Placebo |
| Enrollment | 50 |
| Start date | Jun 1, 2003 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Sep 2, 2005 |
| Last update posted | Dec 9, 2009 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: